Disease · HP_0002197

Generalized-onset seizure

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Generalized-onset seizure. Diseases, record HP_0002197. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002197

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Generalized-onset seizure
Open Targets ID: HP_0002197
Other names: Generalised onset seizure, Generalised seizures, Generalized seizures, Generalized-onset seizures, Primary generalised seizure, Primary generalized seizure
Highest stage of its drugs: Phase 3, for 3 of its 6 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEVETIRACETAM	CHEMBL1286	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BRIVARACETAM	CHEMBL607400	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TOPIRAMATE	CHEMBL220492	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PERAMPANEL	CHEMBL1214124	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LAMOTRIGINE	CHEMBL741	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
VALPROIC ACID	CHEMBL109	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets40

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GRIA1	Glutamate receptor ionotropic AMPA	2	Glutamate receptor ionotropic AMPA antagonist	Phase 3	https://conductscience.org/library/genes/2890	Drugs and targets
GRIA2	Glutamate receptor ionotropic AMPA	2	Glutamate receptor ionotropic AMPA antagonist	Phase 3	https://conductscience.org/library/genes/2891	Drugs and targets
GRIA3	Glutamate receptor ionotropic AMPA	2	Glutamate receptor ionotropic AMPA antagonist	Phase 3	https://conductscience.org/library/genes/2892	Drugs and targets
GRIA4	Glutamate receptor ionotropic AMPA	2	Glutamate receptor ionotropic AMPA antagonist	Phase 3	https://conductscience.org/library/genes/2893	Drugs and targets
SCN10A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6329	Drugs and targets

1 to 10 of 40

See all 40 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01364597	Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy	Phase 3	257	2022-08-29	Epilepsy	BRIVARACETAM	Its record names the disease	ClinicalTrials.gov
NCT00870688	Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening		82	2009-03-27	Epilepsy	VALPROIC ACID	Open Targets' reading of its record	ClinicalTrials.gov
NCT00916149	Cognitive Effects of Treatment of Interictal Discharges	Not applicable	31	2018-08-07	Epilepsy	LAMOTRIGINE, LEVETIRACETAM	Its record names the disease	ClinicalTrials.gov
NCT00150748	Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy	Phase 3	217		Generalized Epilepsy	LEVETIRACETAM	Open Targets' reading of its record	ClinicalTrials.gov
NCT00236704	A Study of the Efficacy and Safety of Topiramate as "Add on" Treatment in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures	Phase 3	80		Epilepsy, Seizures	TOPIRAMATE	Its record names the disease	ClinicalTrials.gov
NCT03780907	Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy	Phase 2	18		Epilepsy	PERAMPANEL	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40737960	RESULT	1	PubMed
37597326	RESULT	1	PubMed
10227614	RESULT	1	PubMed
35305920	DERIVED	1	PubMed
26899665	DERIVED	1	PubMed
22050371	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0002197

GET https://conductscience.org/api/diseases/v1/HP_0002197/targets?page=2

API reference For AI assistants